Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Expected to Announce Quarterly Sales of $103.83 Million

Wall Street analysts expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to announce sales of $103.83 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Amphastar Pharmaceuticals’ earnings. The lowest sales estimate is $101.90 million and the highest is $106.30 million. Amphastar Pharmaceuticals posted sales of $83.43 million in the same quarter last year, which suggests a positive year-over-year growth rate of 24.5%. The business is scheduled to report its next earnings report on Friday, November 5th.

According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full year sales of $418.78 million for the current financial year, with estimates ranging from $410.40 million to $431.13 million. For the next year, analysts forecast that the company will report sales of $472.93 million, with estimates ranging from $452.80 million to $502.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Sunday, August 8th. The company reported $0.21 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.21. Amphastar Pharmaceuticals had a net margin of 2.72% and a return on equity of 8.01%.

A number of research firms recently commented on AMPH. Northland Securities restated a “buy” rating and issued a $23.00 price objective on shares of Amphastar Pharmaceuticals in a report on Tuesday, July 20th. TheStreet upgraded Amphastar Pharmaceuticals from a “c+” rating to a “b” rating in a report on Wednesday, June 9th.

NASDAQ:AMPH traded up $0.04 during mid-day trading on Friday, reaching $18.02. The stock had a trading volume of 741 shares, compared to its average volume of 199,354. The business’s 50 day moving average is $19.75 and its 200 day moving average is $19.09. Amphastar Pharmaceuticals has a fifty-two week low of $16.91 and a fifty-two week high of $21.63. The stock has a market cap of $865.54 million, a P/E ratio of 85.62 and a beta of 0.74. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.50 and a quick ratio of 1.71.

In related news, EVP Rong Zhou sold 5,187 shares of the firm’s stock in a transaction on Tuesday, July 20th. The stock was sold at an average price of $20.57, for a total value of $106,696.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Yakob Liawatidewi sold 31,524 shares of the firm’s stock in a transaction on Thursday, July 15th. The stock was sold at an average price of $20.01, for a total value of $630,795.24. Following the completion of the transaction, the executive vice president now directly owns 77,927 shares of the company’s stock, valued at $1,559,319.27. The disclosure for this sale can be found here. Insiders sold 52,711 shares of company stock valued at $1,066,412 over the last three months. 28.40% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. FORA Capital LLC bought a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at $27,000. Captrust Financial Advisors lifted its holdings in shares of Amphastar Pharmaceuticals by 1,889.3% during the first quarter. Captrust Financial Advisors now owns 1,492 shares of the company’s stock valued at $27,000 after acquiring an additional 1,417 shares during the period. Quantbot Technologies LP lifted its holdings in shares of Amphastar Pharmaceuticals by 866.7% during the first quarter. Quantbot Technologies LP now owns 2,900 shares of the company’s stock valued at $53,000 after acquiring an additional 2,600 shares during the period. Ensign Peak Advisors Inc bought a new position in shares of Amphastar Pharmaceuticals during the first quarter valued at $59,000. Finally, Lazard Asset Management LLC bought a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at $70,000. 56.53% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs.

Further Reading: Trading Stocks – What are percentage gainers?

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.